ArticleScientific reports2021
An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.Endocrine-related cancer · 2026Guideline
- Global research trends in gastroenteropancreatic neuroendocrine tumors: a bibliometric analysis from 2000 to 2023.Frontiers in oncology · 2025Pooled it
- Rectal Neuroendocrine Tumours: A 10-Year Review of Clinical Presentation, Pathological Features, and Treatment Outcomes from a Tertiary Care Cancer Centre in Western India.Indian journal of surgical oncology · 2026Article
- Epidemiologic Trends and Factors Associated With Overall Survival for Patients With Hepatobiliary Neuroendocrine Neoplasms in the United States.Cancer reports (Hoboken, N.J.) · 2025Article
- Attribute Preferences for Somatostatin Analogues in Neuroendocrine Tumours (NETs) Among Patients, Clinicians and Nurses in Australia.Cancer medicine · 2025Article
- Rectal neuroendocrine tumors in a Latin American population: Insights from a Peruvian national cancer institute.World journal of gastrointestinal oncology · 2025Article
- Long-term outcomes of endoscopic resection of 1-1.5 cm sized grade 1 rectal neuroendocrine tumor: A retrospective study.World journal of gastroenterology · 2025Article
- Article
- Charting the Course: Insights into Neuroendocrine Tumor Dynamics in the United States.Annals of surgery · 2025Article
- Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.Oncology and therapy · 2025Article
- Innovative approaches in predicting outcomes for rectal neuroendocrine tumors.World journal of gastroenterology · 2025Review
- A Novel Liver Metastasis Score for Patients Undergoing Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: A Multi-institutional Study.Annals of surgical oncology · 2025Article
- Rectal neuroendocrine tumor during anorectal surgery: three case reports and a review of the literature.Frontiers in oncology · 2025Article
- Epidemiology of Neuroendocrine Neoplasia Worldwide: A Review of the Literature (2012-2022).Neuroendocrinology · 2025Review
- Validation of WHO 2017 Classification and Identification of Prognostic Factors in Patients with Pancreatic Neuroendocrine Neoplasms: A Real-World Experience in Taiwan.Journal of Cancer · 2025Article
- Epidemiological insights and survival patterns in neuroendocrine neoplasia: a geographic perspective.Endocrine oncology (Bristol, England) · 2025Review
- Outcome of Endoscopic Resection of Rectal Neuroendocrine Tumors ≤ 10 mm.Diagnostics (Basel, Switzerland) · 2024Article
- [Clinical significance of neuroendocrine tumors : Incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management].Radiologie (Heidelberg, Germany) · 2024Review
- Sex Differences in the Survival of Patients with Neuroendocrine Neoplasms: A Comparative Study of Two National Databases.Cancers · 2024Article
- Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide.Medicina (Kaunas, Lithuania) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of neuroendocrine tumors (NETs) has been increasing in recent decades. Previously, we reported the incidence and survival of NETs in Taiwan by analyzing the 1996-2008 data from the Taiwan Cancer Registry. Here we performed an updated analysis on the incidence and survival of NETs in Taiwan from 1996 to 2015. The incidence of NETs was 0.244 per 100,000 in 1996 and increased to 3.162 per 100,000 in 2015. The most common site of NETs was rectum (29.65%), followed by lung/bronchus (17.22%), and pancreas (10.71%). The 5- and 10-year overall survival rates of all NETs were 54.6% and 45.3%, respectively. Female and younger NETs patients had a better survival. The survival of all NETs diagnosed between 2010 and 2015 was better than those diagnosed between 2004 and 2009. Among the common sites of NETs, an improved survival of pancreatic NETs diagnosed between 2010 and 2015 compared to those diagnosed between 2004 and 2009 was observed. Overall, the incidence of NETs in Taiwan has continued to increase. The survival of pancreatic NET has shown a recent improvement. The development of novel therapeutic agents has the potential to improve the prognosis of NETs of other sites in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.